Krka d. d (KRK) - Net Assets
Based on the latest financial reports, Krka d. d (KRK) has net assets worth zł2.38 Billion PLN (≈ $654.23 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł3.04 Billion ≈ $837.38 Million USD) and total liabilities (zł665.51 Million ≈ $183.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Krka d. d asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł2.38 Billion |
| % of Total Assets | 78.13% |
| Annual Growth Rate | 5.58% |
| 5-Year Change | 23.87% |
| 10-Year Change | 64.57% |
| Growth Volatility | 3.04 |
Krka d. d - Net Assets Trend (2010–2025)
This chart illustrates how Krka d. d's net assets have evolved over time, based on quarterly financial data. Check how tangible is Krka d. d's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Krka d. d (2010–2025)
The table below shows the annual net assets of Krka d. d from 2010 to 2025. For live valuation and market cap data, see market value of Krka d. d.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | zł2.38 Billion ≈ $654.23 Million |
+6.23% |
| 2024-12-31 | zł2.24 Billion ≈ $615.87 Million |
+2.57% |
| 2023-12-31 | zł2.18 Billion ≈ $600.45 Million |
+2.02% |
| 2022-12-31 | zł2.14 Billion ≈ $588.55 Million |
+11.43% |
| 2021-12-31 | zł1.92 Billion ≈ $528.16 Million |
+9.55% |
| 2020-12-31 | zł1.75 Billion ≈ $482.12 Million |
+5.06% |
| 2019-12-31 | zł1.67 Billion ≈ $458.92 Million |
+8.26% |
| 2018-12-31 | zł1.54 Billion ≈ $423.90 Million |
+3.53% |
| 2017-12-31 | zł1.49 Billion ≈ $409.44 Million |
+2.99% |
| 2016-12-31 | zł1.44 Billion ≈ $397.53 Million |
+2.74% |
| 2015-12-31 | zł1.41 Billion ≈ $386.95 Million |
+4.00% |
| 2014-12-31 | zł1.35 Billion ≈ $372.06 Million |
+1.45% |
| 2013-12-31 | zł1.33 Billion ≈ $366.75 Million |
+7.42% |
| 2012-12-31 | zł1.24 Billion ≈ $341.41 Million |
+8.84% |
| 2011-12-31 | zł1.14 Billion ≈ $313.68 Million |
+8.21% |
| 2010-12-31 | zł1.05 Billion ≈ $289.89 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Krka d. d's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 166.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł2.28 Billion | 96.66% |
| Other Components | zł78.71 Million | 3.34% |
| Total Equity | zł2.36 Billion | 100.00% |
Krka d. d Competitors by Market Cap
The table below lists competitors of Krka d. d ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Puig Brands SA
MC:PUIG
|
$9.36 Billion |
|
Banca Transilvania S.A.
RO:TLV
|
$9.37 Billion |
|
Affiliated Managers Group Inc
NYSE:AMG
|
$9.37 Billion |
|
Trelleborg AB (publ)
ST:TREL-B
|
$9.37 Billion |
|
Eastroc Beverage Group Co Ltd
SHG:605499
|
$9.34 Billion |
|
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
|
$9.34 Billion |
|
Hengyi Petrochemical Co Ltd
SHE:000703
|
$9.34 Billion |
|
Masimo Corporation
NASDAQ:MASI
|
$9.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Krka d. d's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,218,183,000 to 2,358,652,000, a change of 140,469,000 (6.3%).
- Net income of 403,236,000 contributed positively to equity growth.
- Dividend payments of 251,962,000 reduced retained earnings.
- Share repurchases of 61,556,000 reduced equity.
- Other comprehensive income increased equity by 14,572,000.
- Other factors increased equity by 36,179,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł403.24 Million | +17.1% |
| Dividends Paid | zł251.96 Million | -10.68% |
| Share Repurchases | zł61.56 Million | -2.61% |
| Other Comprehensive Income | zł14.57 Million | +0.62% |
| Other Changes | zł36.18 Million | +1.53% |
| Total Change | zł- | 6.33% |
Book Value vs Market Value Analysis
This analysis compares Krka d. d's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 36.05x to 14.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | zł31.12 | zł1122.00 | x |
| 2011-12-31 | zł33.89 | zł1122.00 | x |
| 2012-12-31 | zł37.23 | zł1122.00 | x |
| 2013-12-31 | zł40.34 | zł1122.00 | x |
| 2014-12-31 | zł41.22 | zł1122.00 | x |
| 2015-12-31 | zł43.16 | zł1122.00 | x |
| 2016-12-31 | zł44.54 | zł1122.00 | x |
| 2017-12-31 | zł46.15 | zł1122.00 | x |
| 2018-12-31 | zł48.04 | zł1122.00 | x |
| 2019-12-31 | zł52.41 | zł1122.00 | x |
| 2020-12-31 | zł55.52 | zł1122.00 | x |
| 2021-12-31 | zł61.09 | zł1122.00 | x |
| 2022-12-31 | zł68.19 | zł1122.00 | x |
| 2023-12-31 | zł69.85 | zł1122.00 | x |
| 2024-12-31 | zł72.06 | zł1122.00 | x |
| 2025-12-31 | zł77.69 | zł1122.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Krka d. d utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.10%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.76%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.29x
- Recent ROE (17.10%) is above the historical average (13.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 16.26% | 16.93% | 0.68x | 1.41x | zł65.85 Million |
| 2011 | 14.30% | 15.14% | 0.70x | 1.35x | zł48.98 Million |
| 2012 | 12.91% | 13.99% | 0.70x | 1.31x | zł36.01 Million |
| 2013 | 12.98% | 14.39% | 0.68x | 1.32x | zł39.71 Million |
| 2014 | 12.31% | 13.95% | 0.66x | 1.33x | zł31.16 Million |
| 2015 | 11.27% | 13.59% | 0.64x | 1.29x | zł17.77 Million |
| 2016 | 7.51% | 9.23% | 0.61x | 1.32x | zł-35.89 Million |
| 2017 | 10.26% | 12.05% | 0.66x | 1.29x | zł3.93 Million |
| 2018 | 11.35% | 13.11% | 0.67x | 1.29x | zł20.83 Million |
| 2019 | 14.75% | 16.44% | 0.68x | 1.31x | zł79.11 Million |
| 2020 | 16.69% | 18.96% | 0.69x | 1.28x | zł116.66 Million |
| 2021 | 16.23% | 19.75% | 0.62x | 1.33x | zł118.69 Million |
| 2022 | 17.15% | 21.15% | 0.64x | 1.27x | zł151.43 Million |
| 2023 | 14.52% | 17.38% | 0.65x | 1.28x | zł97.74 Million |
| 2024 | 16.09% | 18.69% | 0.67x | 1.28x | zł135.17 Million |
| 2025 | 17.10% | 19.76% | 0.67x | 1.29x | zł167.37 Million |
Industry Comparison
This section compares Krka d. d's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $363,246,000
- Average return on equity (ROE) among peers: -21.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Krka d. d (KRK) | zł2.38 Billion | 16.26% | 0.28x | $9.36 Billion |
| Celon Pharma SA (CLN) | $363.25 Million | -21.85% | 0.26x | $219.00 Million |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more